Fundamentals for Gilead Sciences, Inc.
GILD is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profi...
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - General
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Revenue projections:
Financial Ratios:
| currentRatio | 1.265000 |
|---|---|
| forwardPE | 14.636303 |
| debtToEquity | 223.465000 |
| earningsGrowth | 0.000000 |
| revenueGrowth | 0.102000 |
| grossMargins | 0.796040 |
| operatingMargins | 0.336790 |
| trailingEps | -2.650000 |
| forwardEps | 9.889110 |
GILD's current ratio being 1.265 suggests that it has more than enough liquidity to cover short-term debt obligations. The company's cash reserves and current assets are sufficient to meet immediate liabilities, signaling solid financial health and minimal risk.
Gilead Sciences, Inc.'s Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
Gilead Sciences, Inc.'s elevated debt-to-equity ratio suggests that the company is using significant debt to finance its operations. This level of leverage can amplify financial risk, particularly if profitability decreases or external conditions become unfavorable.
Positive gross and operating margins for GILD demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
Price projections:
Insider Transactions:
GILD experienced 34 sell transactions with market price of 130.7561430089614 per share.There were no sell transactions during the given timeframe.More recent purchases than sales at current price levels for GILD could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.
Recommendation changes over time:
GILD has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see GILD as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.
